SCHEMBL6177967

SCHEMBL6177967

Nc1c(Cl)cc(C(=O)O)c2nc(Cl)cn12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 1/20 0.41
HTR4 Q13639 1/20 0.41
KCNH2 Q12809 1/20 0.38
MAPT P10636 5/20 0.35
KDM4E B2RXH2 4/20 0.35
POLB P06746 3/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
TSHR P16473 2/20 0.34
CYP3A4 P08684 1/20 0.34
KEAP1 Q14145 1/20 0.33
NFE2L2 Q16236 1/20 0.33
CASP1 P29466 2/20 0.33
HSD17B10 Q99714 2/20 0.33
CASP7 P55210 1/20 0.33
SLC9A1 P19634 1/20 0.33
ALDH1A1 P00352 4/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5889550 0.85 HTR3A (0.56) HTR3AHTR4KCNH2MAPTKDM4E
SCHEMBL6178061 0.81 KCNH2 (0.41) HTR3AHTR4KCNH2MAPTKDM4E
SCHEMBL5777321 0.81 HTR3A (0.43) HTR3AHTR4KCNH2MAPTKDM4E
SCHEMBL6178995 0.80 DHODH (0.48) MAPTKDM4ENPC1RAB9ACASP1
SCHEMBL6178115 0.80 HTR3A (0.42) HTR3AHTR4KCNH2KDM4ETSHR
SCHEMBL6762031 0.79 BAZ2B (0.45) HTR3AHTR4KCNH2KDM4ENPC1
SCHEMBL6177612 0.76 GABRP (0.41) MAPTKDM4ENPC1RAB9ATDP1
SCHEMBL6177253 0.75 GRIN2D (0.36) MAPTKDM4EPOLBNPC1RAB9A
SCHEMBL5889429 0.70 GABRP (0.38) HTR3AHTR4KDM4ETDP1TSHR
SCHEMBL6177033 0.67 GAA (0.44) HTR3AHTR4KCNH2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1440071-B1 IMIDAZOPYRIDINE COMPOUNDS AS 5-HT 4? RECEPTOR MODULATORS PFIZER (US) 2005-10-26 EP disclosed
US-20040034226-A1 Imidazopyridine compounds as 5-HT4 receptor modulators UCHIDA CHIKARA (JP) 2004-02-19 US disclosed
US-6624162-B2 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, Functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. PFIZER INC. 2003-09-23 US disclosed
US-20030092699-A1 Imidazopyridine compounds as 5-HT4 receptor modulators PFIZER INC. 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092699-A1 Imidazopyridine compounds as 5-HT4 receptor modulators HTR4, HRH4, HRH2 HTR3A 28/4885HTR4 1/4885KCNH2 962/4885
US-20040034226-A1 Imidazopyridine compounds as 5-HT4 receptor modulators HRH4, HTR4, HRH2 HTR3A 27/4885HTR4 2/4885KCNH2 895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.